Elena Battistello

Analyst, Novartis Venture Fund

2023

• Led the initial assessment of new technologies in different therapeutic areas, at both preclinical and clinical stages • Contributed to all stages of scientific and business due diligence with particular emphasis on the scientific aspect of the investment • Supported two portfolio companies across their development as board observer

Postdoctoral Fellow

2020 - 2023

Department of Pathology, NYU School of Medicine • Directed research projects aimed at dissecting the epigenetic regulation of T cell exhaustion to improve T-cell therapies efficacy in hematological tumors (Battistello*, Hixon*, Comstock* et al, Molecular Cell, 2023) • Used single-cell transcriptomic and epigenomic tools to assess response to targeted or CAR-T therapy • Raised funding through the Swiss National Science Foundation and the Lymphoma Research Foundation ($185,700 total)

Postdoctoral Fellow

2019 - 2019

• Led research activities targeting therapy resistance in lymphoma • Developed a screening pipeline currently used for drug discovery

PhD Student

2015 - 2019

Swiss Institute for Experimental Cancer Research, EPFL Department of Computational Biology, University of Lausanne • Directed translational research projects aimed at identifying novel therapeutic targets and immunotherapy approaches in hematological tumors (Dheilly*, Battistello* et al., Cancer Cell, 2020; Battistello et al., Blood, 2018) • Supervised undergraduate students and served as teaching assistant at Cancer Biology courses

Internship

2015 - 2015

Internship

2014 - 2014

Internship

2012 - 2012